|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARNT |
Gene summary for ARNT |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARNT | Gene ID | 405 |
| Gene name | aryl hydrocarbon receptor nuclear translocator | |
| Gene Alias | HIF-1-beta | |
| Cytomap | 1q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A8K6P0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 405 | ARNT | LZE4T | Human | Esophagus | ESCC | 2.83e-09 | 2.88e-01 | 0.0811 |
| 405 | ARNT | LZE5T | Human | Esophagus | ESCC | 8.14e-07 | 2.88e-01 | 0.0514 |
| 405 | ARNT | LZE7T | Human | Esophagus | ESCC | 4.11e-05 | 3.03e-01 | 0.0667 |
| 405 | ARNT | LZE8T | Human | Esophagus | ESCC | 2.93e-02 | 7.32e-02 | 0.067 |
| 405 | ARNT | LZE20T | Human | Esophagus | ESCC | 3.61e-03 | 1.49e-01 | 0.0662 |
| 405 | ARNT | LZE22T | Human | Esophagus | ESCC | 1.19e-05 | 3.41e-01 | 0.068 |
| 405 | ARNT | LZE24T | Human | Esophagus | ESCC | 8.17e-17 | 2.11e-01 | 0.0596 |
| 405 | ARNT | P1T-E | Human | Esophagus | ESCC | 1.51e-02 | 1.55e-01 | 0.0875 |
| 405 | ARNT | P2T-E | Human | Esophagus | ESCC | 3.24e-12 | 2.25e-01 | 0.1177 |
| 405 | ARNT | P4T-E | Human | Esophagus | ESCC | 4.41e-09 | 1.81e-01 | 0.1323 |
| 405 | ARNT | P5T-E | Human | Esophagus | ESCC | 1.50e-07 | 2.04e-01 | 0.1327 |
| 405 | ARNT | P8T-E | Human | Esophagus | ESCC | 1.56e-10 | 2.69e-01 | 0.0889 |
| 405 | ARNT | P9T-E | Human | Esophagus | ESCC | 1.49e-09 | 1.99e-01 | 0.1131 |
| 405 | ARNT | P10T-E | Human | Esophagus | ESCC | 1.82e-08 | 1.22e-01 | 0.116 |
| 405 | ARNT | P11T-E | Human | Esophagus | ESCC | 2.23e-07 | 3.67e-01 | 0.1426 |
| 405 | ARNT | P12T-E | Human | Esophagus | ESCC | 1.67e-06 | 2.01e-01 | 0.1122 |
| 405 | ARNT | P15T-E | Human | Esophagus | ESCC | 1.79e-22 | 4.33e-01 | 0.1149 |
| 405 | ARNT | P16T-E | Human | Esophagus | ESCC | 1.76e-14 | 1.83e-01 | 0.1153 |
| 405 | ARNT | P17T-E | Human | Esophagus | ESCC | 8.03e-05 | 2.96e-01 | 0.1278 |
| 405 | ARNT | P19T-E | Human | Esophagus | ESCC | 3.14e-05 | 3.57e-01 | 0.1662 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:006082820 | Thyroid | HT | regulation of canonical Wnt signaling pathway | 29/1272 | 253/18723 | 4.01e-03 | 2.96e-02 | 29 |
| GO:003051825 | Thyroid | HT | intracellular steroid hormone receptor signaling pathway | 16/1272 | 116/18723 | 5.21e-03 | 3.48e-02 | 16 |
| GO:003011120 | Thyroid | HT | regulation of Wnt signaling pathway | 35/1272 | 328/18723 | 5.41e-03 | 3.58e-02 | 35 |
| GO:005076715 | Thyroid | HT | regulation of neurogenesis | 38/1272 | 364/18723 | 5.56e-03 | 3.64e-02 | 38 |
| GO:00020661 | Thyroid | HT | columnar/cuboidal epithelial cell development | 8/1272 | 44/18723 | 8.78e-03 | 4.95e-02 | 8 |
| GO:0010498113 | Thyroid | PTC | proteasomal protein catabolic process | 297/5968 | 490/18723 | 4.58e-40 | 9.63e-37 | 297 |
| GO:0043161113 | Thyroid | PTC | proteasome-mediated ubiquitin-dependent protein catabolic process | 254/5968 | 412/18723 | 3.91e-36 | 4.54e-33 | 254 |
| GO:0006979113 | Thyroid | PTC | response to oxidative stress | 234/5968 | 446/18723 | 6.97e-20 | 9.77e-18 | 234 |
| GO:0062197113 | Thyroid | PTC | cellular response to chemical stress | 180/5968 | 337/18723 | 1.36e-16 | 1.16e-14 | 180 |
| GO:00064737 | Thyroid | PTC | protein acetylation | 116/5968 | 201/18723 | 3.05e-14 | 1.92e-12 | 116 |
| GO:0016055110 | Thyroid | PTC | Wnt signaling pathway | 217/5968 | 444/18723 | 3.71e-14 | 2.30e-12 | 217 |
| GO:00435437 | Thyroid | PTC | protein acylation | 134/5968 | 243/18723 | 4.22e-14 | 2.58e-12 | 134 |
| GO:0198738110 | Thyroid | PTC | cell-cell signaling by wnt | 217/5968 | 446/18723 | 6.68e-14 | 3.73e-12 | 217 |
| GO:0034599113 | Thyroid | PTC | cellular response to oxidative stress | 151/5968 | 288/18723 | 2.82e-13 | 1.43e-11 | 151 |
| GO:0030111110 | Thyroid | PTC | regulation of Wnt signaling pathway | 163/5968 | 328/18723 | 1.05e-11 | 4.29e-10 | 163 |
| GO:0048545113 | Thyroid | PTC | response to steroid hormone | 158/5968 | 339/18723 | 8.10e-09 | 2.00e-07 | 158 |
| GO:0060828110 | Thyroid | PTC | regulation of canonical Wnt signaling pathway | 123/5968 | 253/18723 | 1.83e-08 | 4.26e-07 | 123 |
| GO:0060070110 | Thyroid | PTC | canonical Wnt signaling pathway | 141/5968 | 303/18723 | 5.71e-08 | 1.21e-06 | 141 |
| GO:003052228 | Thyroid | PTC | intracellular receptor signaling pathway | 126/5968 | 265/18723 | 6.31e-08 | 1.31e-06 | 126 |
| GO:003292219 | Thyroid | PTC | circadian regulation of gene expression | 43/5968 | 68/18723 | 1.03e-07 | 2.05e-06 | 43 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
| hsa0521118 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
| hsa0406629 | Esophagus | ESCC | HIF-1 signaling pathway | 75/4205 | 109/8465 | 3.66e-05 | 1.68e-04 | 8.60e-05 | 75 |
| hsa05208310 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
| hsa0521119 | Esophagus | ESCC | Renal cell carcinoma | 51/4205 | 69/8465 | 3.29e-05 | 1.53e-04 | 7.83e-05 | 51 |
| hsa04066113 | Esophagus | ESCC | HIF-1 signaling pathway | 75/4205 | 109/8465 | 3.66e-05 | 1.68e-04 | 8.60e-05 | 75 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ARNT | GOB | Colorectum | CRC | SGSM3,TNFAIP8,ZG16, etc. | 3.07e-02 |  |
| ARNT | IMGOB | Colorectum | FAP | SGSM3,TNFAIP8,ZG16, etc. | 2.13e-01 |  |
| ARNT | PLA | Lung | AIS | IGHA1,SELENOM,AP000787.1, etc. | 1.22e-01 |  |
| ARNT | CD8TEREX | Lung | MIAC | FYCO1,DENND2C,C11orf80, etc. | 3.70e-02 |  |
| ARNT | COR | Oral cavity | LP | TBC1D12,APBB1,DGKD, etc. | 2.28e-01 |  |
| ARNT | GRA | Oral cavity | LP | TBC1D12,APBB1,DGKD, etc. | 2.90e-01 | |
| ARNT | GRA | Oral cavity | OSCC | TBC1D12,APBB1,DGKD, etc. | 1.35e-01 |  |
| ARNT | MSC.PVA | Skin | ADJ | FEM1B,MT-ND6,AC092683.1, etc. | 1.48e-02 |  |
| ARNT | MSC.PVA | Skin | AK | FEM1B,MT-ND6,AC092683.1, etc. | 1.11e-16 |  |
| ARNT | ADIPO | Skin | SCCIS | FEM1B,MT-ND6,AC092683.1, etc. | 0.00e+00 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARNT | SNV | Missense_Mutation | rs777162532 | c.593N>C | p.Asn198Thr | p.N198T | P27540 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A1G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| ARNT | SNV | Missense_Mutation | c.2033N>T | p.Ser678Phe | p.S678F | P27540 | protein_coding | tolerated_low_confidence(0.23) | benign(0.122) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| ARNT | SNV | Missense_Mutation | c.1106N>C | p.Ile369Thr | p.I369T | P27540 | protein_coding | tolerated(0.9) | benign(0) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| ARNT | SNV | Missense_Mutation | c.2281N>C | p.Glu761Gln | p.E761Q | P27540 | protein_coding | deleterious_low_confidence(0) | benign(0.26) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ARNT | SNV | Missense_Mutation | rs777162532 | c.593N>C | p.Asn198Thr | p.N198T | P27540 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A1KT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
| ARNT | SNV | Missense_Mutation | rs777162532 | c.593N>C | p.Asn198Thr | p.N198T | P27540 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AQ-A1H3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| ARNT | SNV | Missense_Mutation | rs777162532 | c.593N>C | p.Asn198Thr | p.N198T | P27540 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A1EX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| ARNT | SNV | Missense_Mutation | rs777162532 | c.593N>C | p.Asn198Thr | p.N198T | P27540 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A1F2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ARNT | SNV | Missense_Mutation | novel | c.1427N>A | p.Ser476Tyr | p.S476Y | P27540 | protein_coding | deleterious(0) | possibly_damaging(0.73) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| ARNT | SNV | Missense_Mutation | c.1403N>A | p.Ser468Asn | p.S468N | P27540 | protein_coding | tolerated(0.21) | benign(0) | TCGA-D8-A143-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 405 | ARNT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | HYDROCORTISONE | HYDROCORTISONE | 10048155 | |
| 405 | ARNT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | TCDD | 9787404,11026553,9579024,14687977 | ||
| 405 | ARNT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | FUROSPONGOLIDE | FUROSPONGOLIDE | 18989978 | |
| 405 | ARNT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | PROTEASOME INHIBITOR | 10409767 | ||
| 405 | ARNT | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | EPICATECHIN GALLATE | EPICATECHIN GALLATE | 15620252 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |